Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANACHE: Neladenoson Bialanate in HFpEF
NCT03098979Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of neladenoson bialanate in heart failure with preserved ejection fraction (HFpEF), sponsored by Bayer. Started May 2017; status: completed.
02
Drugs
neladenoson bialanate
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03098979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098979.